{"References": [{"title": "Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus", "authors": "Julio Rosenstock, Carol Wysham, Juan P. Frías, Shizuka Kaneko, Clare J. Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Stefano Karanikas, Axel Haupt", "journal": "Expert Review of Endocrinology & Metabolism", "year": "2021", "volumes": "16", "first page": "251", "last page": "261", "DOI": "10.1080/17446651.2021.1925927"}, {"title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity", "authors": "John P.H. Wilding, Rachel L. Batterham, Salvatore Calanna, Melanie Davies, Luc F. Van Gaal, Ildiko Lingvay, Barbara M. McGowan, Julio Rosenstock, Marie T.D. Tran, Thomas A. Wadden, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F. Kushner", "journal": "New England Journal of Medicine", "year": "2021", "volumes": "384", "first page": "989", "last page": "1002", "DOI": "10.1056/NEJMoa2032183"}, {"title": "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial", "authors": "Julio Rosenstock, Carol Wysham, Juan P. Frías, Shizuka Kaneko, Clare J. Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Stefano Karanikas, Axel Haupt", "journal": "The Lancet", "year": "2021", "volumes": "398", "first page": "143", "last page": "155", "DOI": "10.1016/S0140-6736(21)01324-6"}, {"title": "Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5", "authors": "Melanie Davies, Luc F. Van Gaal, Sten Madsbad, Timothy J. Philis-Tsimikas, Domenica Rubino, Carel W. le Roux, Ofri Mosenzon, Altynai Satylganova, Niels Zeuthen, John P.H. Wilding", "journal": "Obesity", "year": "2022", "volumes": "30", "first page": "1422", "last page": "1436", "DOI": "10.1002/oby.23422"}, {"title": "Emerging GLP-1 receptor agonists for treating diabetes and obesity", "authors": "Daniel J. Drucker", "journal": "Cell Metabolism", "year": "2022", "volumes": "34", "first page": "1553", "last page": "1568", "DOI": "10.1016/j.cmet.2022.08.013"}, {"title": "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes", "authors": "Juan P. Frías, Melanie J. Davies, Julio Rosenstock, Laura Fernández Landó, Deborah Bergman, Bingqing Liu, Jing Cui, Richard E. Brown", "journal": "New England Journal of Medicine", "year": "2021", "volumes": "385", "first page": "503", "last page": "515", "DOI": "10.1056/NEJMoa2107519"}, {"title": "A Novel Unimolecular GLP-1/GIP/Glucagon Triple Receptor Agonist Exhibits Weight-Lowering and Diabetes-Improving Effects", "authors": "Xinchen Wang, Yue Dai, Zhiyi Han, Yue Li, Jing Li, Yuxin Zhang, Yimei Du, Qing Xu, Yun Tang, Dehua Yang, Ming-Wei Wang", "journal": "ACS Pharmacology & Translational Science", "year": "2021", "volumes": "4", "first page": "701", "last page": "713", "DOI": "10.1021/acsptsci.0c00193"}, {"title": "Dual and triple receptor agonists based on GLP-1, glucagon, and GIP for the treatment of metabolic diseases", "authors": "Matthias Tschöp, Brian Finan, Christoffer Clemmensen, Timo Müller, Richard DiMarchi", "journal": "Molecular Metabolism", "year": "2022", "volumes": "57", "first page": "101351", "last page": "", "DOI": "10.1016/j.molmet.2021.101351"}, {"title": "Nutrient-Stimulated Hormone-Based Therapies for Obesity and Related Metabolic Diseases", "authors": "Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp", "journal": "Cell Metabolism", "year": "2022", "volumes": "34", "first page": "1586", "last page": "1604", "DOI": "10.1016/j.cmet.2022.09.004"}, {"title": "Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases", "authors": "Timo D. Müller, Brian Finan, Christoffer Clemmensen, Richard D. DiMarchi, Matthias H. Tschöp", "journal": "Nature Reviews Endocrinology", "year": "2019", "volumes": "15", "first page": "90", "last page": "104", "DOI": "10.1038/s41574-018-0118-x"}]}